Tirzepatide

Dual GIP / GLP‑1 agonist · Weight · Metabolic

The dual incretin at the centre of modern metabolic medicine — a strong, replicated evidence base.

Form: 30 mg / 60 mg — pre-reconstituted in the Cellvéra injector
Oversight: Licensed clinician, included
30 mg pen: R3 798 / protocol
60 mg pen: R5 045 / protocol

For research purposes only · Not for human consumption

Begin your intake

Opens a private email to our concierge · nothing is charged

Checkout begins your confidential medical intake. Tirzepatide is dispensed only if a licensed clinician prescribes it after reviewing your intake — nothing is charged until your provider approves.

Pathway

A dual GIP/GLP-1 receptor agonist — the active ingredient in the approved medicines Mounjaro (diabetes) and Zepbound (weight management), and one of the most-studied metabolic drugs of the last decade.

Mechanism

It activates the receptors for two incretin hormones simultaneously. GLP-1 activity reduces appetite, slows gastric emptying and improves insulin secretion; the added GIP activity appears to improve how fat tissue handles energy and may soften the nausea associated with GLP-1 alone.

Studied for

Type 2 diabetes — blood-glucose and HbA1c reduction
Chronic weight management in obesity or overweight with a related condition
Obstructive sleep apnoea (an approved use in some regions)
Cardiovascular and metabolic risk markers

Areas of research interest — not promised outcomes.

Where the evidence stands

The SURPASS trials in diabetes and the SURMOUNT trials in obesity are large, well-run Phase 3 programmes. SURMOUNT-1 reported roughly 20–22% average weight reduction at the higher doses over 72 weeks — a strong, replicated evidence base.

Typical protocol

Titrated from 2.5 mg weekly upward over 20+ weeks, exactly as prescribed and monitored by your supervising clinician.

Contraindications & cautions

Personal/family history of medullary thyroid carcinoma. MEN-2 syndrome. Pancreatitis and gallbladder disease are the serious concerns. Pregnancy or breastfeeding.

Prescribed only after evaluation by your supervising provider, based on your history and bloodwork.

Important safety information

Tirzepatide is dispensed as a compounded preparation under valid prescription only. Compounded medications are not FDA-evaluated for safety or efficacy. Report adverse events to your supervising clinician immediately. Keep refrigerated; keep out of reach of children.

Discussed at consultation

Your clinician may recommend an alternative or a staged protocol.

Retatrutide From R4 599 · View → Tesamorelin From R5 225 · View →